QNRX VS BJDX Stock Comparison

Performance

QNRX
10/100

QNRX returned -81.93% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

BJDX
10/100

BJDX returned -77.09% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Technicals

QNRX
29/100

QNRX receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.

BJDX
18/100

BJDX receives a 17 of 100 based on 14 indicators. 2 are bullish, 11 are bearish.

Earnings

QNRX
10/100

QNRX has missed earnings 5 times in the last 20 quarters.

BJDX
10/100

BJDX has missed earnings 6 times in the last 20 quarters.

Profit

QNRX
10/100

Out of the last 14 quarters, QNRX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

BJDX
10/100

Out of the last 13 quarters, BJDX has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

QNRX
35/100

QNRX has had a lower than average amount of volatility over the last 12 months giving it a score of 35 of 100.

BJDX
50/100

BJDX has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Quoin Pharmaceuticals, Ltd. American Depositary Shares Summary

Nasdaq / QNRX

Healthcare

Biotechnology

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.

Bluejay Diagnostics, Inc. Common Stock Summary

Nasdaq / BJDX

Healthcare

Medical - Devices

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Power up your portfolio